MKI67 and breast carcinoma: The conducted study allowed us to compare the clinical and molecular features, such as age, lymph node metastasis, ER, PR, HER2 status, Ki-67 index and the histopathological malignancy level with the mutations and expressions of genes related to the PI3K/Akt/mTOR pathway in breast cancer.